Rationale: Allogeneic bone marrow-derived mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs) have each entered clinical trials but a direct comparison of these cell types has not been performed in a large animal model of hibernating myocardium.
INTRODUCTION
The development of cell-based therapeutic approaches to treat ischemic heart disease has proceeded at a rapid pace since initial clinical trials commenced over a decade ago. Studies have been fueled by optimism that exogenous stem cells could replenish the pool of functional cardiac myocytes that is depleted by acute and chronic injury. There has been an abundance of positive results in preclinical rodent models of myocardial infarction using a variety of cell types with surprisingly few negative studies. Nevertheless, as research has translated to large animal studies and phase I and 2 clinical trials the functional effects of cell-therapy have been variable. Thus, although clinical trials have confirmed the safety of most preclinical cardiac cell-therapies, limited functional improvement has been observed in comparison to animal studies [1] [2] [3] . This has been highlighted by a recent meta-analysis of clinical cell therapy studies utilizing individual patient data, which concluded that intracoronary cell therapy did not reduce clinical events nor improve left ventricular (LV) function in patients with recent myocardial infarction 4 .
There are several potential explanations for the difficulty in translating preclinical findings to clinical trials. Some are unique to cardiovascular research while others are common to translating preclinical research in other fields of medicine 5 . First, rodents tolerate myocardial infarctions that are much larger than what a human can survive. This amplifies the deleterious effects of LV remodeling in rodent models. At the same time, remodeling in humans is now markedly attenuated by pharmacological therapy and early reperfusion as compared to untreated animal models. In addition, most models employ young animals that do not have the underlying cardiovascular risk factors present in humans with diseases such as hypertension, diabetes and hypercholesterolemia nor the impact of aging. There is also likely publication bias towards positive results with underreporting of negative preclinical studies.
Perhaps a more substantial barrier common to translating preclinical studies in all fields are the way that most are conducted. In comparison to clinical trial methodology, few preclinical studies employ a blinded randomized controlled approach. The team of preclinical investigators and research scientists is rarely blinded to treatment allocation. While interpretation of some aspects are sometimes blinded (e.g. cardiac imaging results), blinding of investigators involved in pathological analysis and other physiological endpoints is rarely employed. A recent meta-analysis of preclinical cardiovascular cell therapy studies found that only 42% of included studies reported blinded assessment of some data and only 11% reported allocation concealment 6 . Thus, many studies may have selection bias related to inclusion/exclusion of experiments and variable observer bias in most of the end-point analyses. These problems have recently been highlighted in the field of cardioprotection research by the NIH-sponsored Consortium for Preclinical Assessment of Cardioprotective Therapies (CAESAR) 7 . Using rigorous blinded treatment and data analysis comparable to randomized clinical trials, the CAESAR consortium has been unable to show the beneficial effects of two agents that had been widely shown to reduce infarct size in prior small, poorly controlled preclinical studies in multiple species 8, 9 . Thus, the absence of a completely blinded randomized study design may be a significant methodological hurdle to overcome in translation of preclinical research into clinical application.
With this in mind, we determined if a randomized blinded experimental approach could be employed in a single-center preclinical trial comparing two types of cell-therapy vs. vehicle-treated controls. Bone marrow-derived mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs) cultured from explanted heart tissue are promising cell types that have recently entered clinical trials [10] [11] [12] [13] . A particularly attractive feature of both cell types is the feasibility of using allogeneic cells, which would permit off-the-shelf availability of cells for treatment and circumvent the need for personalized cell expansion. Both MSCs and CDCs have been shown to improve ventricular function in preclinical studies by our laboratory and others analyses. Therefore, the present study addresses these issues by employing a rigorous, clinical trial-based three-way design to directly compare the therapeutic efficacy of intracoronary allogeneic bone marrowderived mesenchymal stem cells (icMSCs) and intracoronary cardiosphere-derived cells (icCDCs) infused to the entire heart in a swine model of chronic myocardial ischemia. Any potential effects of allogeneic cell rejection were minimized by treating all animals with chronic cyclosporine. The results demonstrate preclinical therapeutic equipoise of allogeneic icMSCs and icCDCs.
METHODS
All procedures and protocols conformed to institutional guidelines for the care and use of animals in research and were approved by the University at Buffalo Institutional Animal Care and Use Committee.
Study design and treatment of data.
All personnel involved in data collection and analysis (including echocardiographic imaging and histological assessment of myocyte morphometry and proliferation) were blinded to the treatment status of each animal. Serial data collection and analysis were conducted by an independent biostatistician not involved in the protocols or assays (JAF). Animals were randomized to receive vehicle, icMSCs, or icCDCs in a 1:1:1 ratio. Regional wall thickening of the area supplied by the left anterior descending coronary artery (LAD %WT) 1-month after treatment was selected as the primary endpoint.
Isolation and characterization of MSCs and CDCs.
Bone marrow (n=2) and left ventricular tissue (n=3) samples were collected from healthy donor pigs (age 8±3 weeks) for the isolation and cultivation of MSCs and CDCs, as previously described 16, 17, 19 and summarized in the Online Supplement. Cells were cultured for 4 to 7 passages, at which time they were collected for characterization by flow cytometry and immunohistochemistry or intracoronary infusion to recipient pigs with hibernating myocardium. Flow cytometric and immunohistochemical characterization included assessment of hematopoietic (CD45, cKit), mesenchymal (CD90, CD105) and cardiac (GATA4, Nkx2.5) markers. Prior to administration, both cell types were filtered through a 30 μm pore filter to circumvent administering cell aggregates (MACS pre-separation filters, Miltenyi Biotec) and suspended in heparinized HBSS solution (3000U heparin in 30ml in total) for intracoronary infusion.
Effects of icMSCs and icCDCs on flow and function in hibernating myocardium.
Experimental groups and the study timeline are summarized in Supplemental Figure I . Pigs (n=34) were chronically instrumented with a 1.5 mm Delrin occluder on the proximal LAD to produce hibernating myocardium as previously described 20 . Briefly, juvenile pigs were sedated (Telazol 100mg/ml / xylazine 100 mg/ml, 0.022 mg/kg i.m.), intubated and ventilated with a 0.5-2% isoflurane-oxygen mixture. Through a small pericardiotomy, the Delrin occluder was placed on the proximal LAD. Antibiotics (cefazolin, 25 mg/kg and gentamicin, 3 mg/kg i.m.) were given 1-hour before surgery and repeated after closing the chest. Analgesia included an intercostal nerve block (0.5% Marcaine) and intramuscular doses of butorphanol (2.2 mg/kg q6h) and flenixin (1-2 mg/kg q.d.).
Serial physiological studies:
Studies began 3-months after instrumentation when stable reductions in LAD wall thickening and perfusion indicative of hibernating myocardium were present 21 . Under propofol sedation (5-10 mg/kg/hr i.v.), a catheter (Millar) was inserted to measure LV pressure and inject microspheres. Regional wall-thickening was assessed with transthoracic echocardiography from a right parasternal approach 16 . All pigs showed anterior dysfunction without dyskinesis. Systolic wall-thickening (ΔWT=ESWT-EDWT; %WT=ΔWT/EDWTx100) was quantified in dysfunctional LAD regions as well as remote, normally-perfused regions of the same heart.
Microsphere perfusion: Microsphere flow was measured at rest and following adenosine vasodilation to characterize hibernating myocardium 3-months after instrumentation and repeated 4-weeks after instrumentation as previously described 22 . Briefly, we injected 15m microspheres (~3x10 6 ) labeled with fluorescing dyes into the left ventricle while a reference arterial sample was withdrawn at 6 ml/min for 90-seconds. At the end of the study, samples were taken from mid-ventricular circumferential rings divided into twelve wedges with each cut into 3 transmural layers. Fluorescent dyes were extracted using standard techniques and quantified at selected excitation wavelengths 23 .
Cell administration and follow-up: After baseline physiological measurements, pigs were randomly assigned to receive coded treatments of either vehicle (n=8), ~35x10 6 icMSCs (n=9), or ~35x10 6 icCDCs (n=9) with all investigators and research personnel blinded to treatment allocation. Each treatment was divided into three aliquots and infused into each of the three major coronary artery distributions over 10-minutes at a rate of 1x10 6 cells/minute. All animals were treated with cyclosporine A beginning 3 days before the baseline study and continuing throughout terminal experiments (200 mg/day p.o., Watson Pharma). Animals returned to the laboratory 4-weeks later for post-treatment physiological studies under propofol anesthesia, after which the heart was arrested with potassium chloride and quickly excised for histopathological analysis.
Myocardial histopathology.
Quantitative immunohistochemistry and morphometry were evaluated in all vehicle-, icMSC-, and icCDCtreated animals with hibernating myocardium. Y-FISH analysis was performed in the subset of female animals that received male donor-derived cells to track cell fate, as described below.
Arteriolar and capillary density:
Regional tissue sections were incubated with anti-α smooth muscle actin and anti-von Willebrand factor antibodies with appropriate fluorescent-labeled secondary antibodies to identify coronary arterioles and capillaries, respectively. Vessels were counted in at least 10 random fields from the subendocardial and subepicardial layers of each tissue sample (LAD and remote) and expressed per tissue area (mm 2 ).
Myocyte nuclear density and morphometry: Paraffin-embedded samples from LAD and non-ischemic remote regions were fixed for morphometry as previously described 16, 17, 24 . PAS-stained sections were used to quantify myocyte diameter by counting at least 100 cells from the inner and outer half of the LAD and remote regions. Myocytes were included regardless of size as long as myofilaments could be identified surrounding the nucleus. Myocyte nuclear density was also assessed in PAS-stained sections as previously described 16 . To evaluate whether changes in nuclear density reflected increases in the number of nuclei per myocyte, longitudinal myocytes (n=20 in each histological sample) that had boundaries that were clearly visible (intercalated discs and the lateral borders of the myocyte) were used to quantify the number of nuclei per cell in each heart using previously published methodology 25 . Point-counting of trichrome-stained sections was used to quantify connective tissue 26 .
Quantification of myocyte proliferation:
Myocardial samples were incubated with anti-Ki67 and antiphospho-Histone-H3 antibodies to identify myocytes in the growth phase of the cell cycle and undergoing mitosis as previously described 17 . Paraffin-fixed sections (4μm thickness) were incubated with either antiKi67 (mouse monoclonal antibody, clone MIB-1, Dako, 1:200) or anti-phospho-histone-H3 (rabbit polyclonal antibody, Upstate Biotech, 1:1000) to detect proliferating cells and anti-cTnI (rabbit polyclonal antibody, Santa Cruz, 1:200) to detect myofilaments. Nuclei were stained with DAPI (Vectasheild).
Fluorescent in situ hybridization (Y-FISH):
Y-FISH (IDLabs, Ontario, Canada) was used to determine the fate of male donor icMSCs (n=4) and icCDCs (n=5) injected into female recipients 17 . Tissue samples were hybridized with FITC-conjugated porcine Y-chromosome probe according to the manufacturer's instructions (IDLabs, Ontario, Canada). Y-FISH staining in male control cardiac tissue was used to correct for the fact that myocyte nuclear diameter was greater than histological slice thickness. The "efficiency" of Y chromosome identification was 37±3% and similar to previously published data 17 . Sections were also incubated with antibodies to cardiac Troponin I to detect co-localization of Y-FISH in myocytes derived from donor cells.
Statistical analysis.
Data are expressed as mean±standard deviation. Differences among treatment groups were assessed by twoway analysis of variance (ANOVA) with repeated measures and the post-hoc Holm-Sidak test. For all comparisons, p<0.05 was considered significant.
RESULTS
A total of 34 animals were instrumented with a chronic LAD stenosis. Consistent with previous data demonstrating an elevated risk of sudden cardiac death in this model 22 , 7 animals died prior to completion of the study. Of these, 5 died prior to the 3-month study and 2 died between the 3-and 4-month studies (1 CDC-treated animal and 1 vehicle-treated animal, >10 days after the intracoronary infusion). One animal was removed from further study at the 3-month time point when angiography demonstrated that there was no stenosis of the LAD and the Delrin occluder had been displaced from the vessel. All remaining animals (n=26) were included in the final data analysis with no exclusions after randomization to treatment.
Allogeneic MSC and CDC cell characterization.
Cell culture resulted in comparable total cell injections from each treatment (32.4±7.3 x10 6 icMSCs and 35.3±5.9 x10 6 icCDCs, p=0.40). Flow cytometry confirmed that cell surface marker expression profiles were consistent with previous reports 16, 17, 27 . At the time of infusion, MSCs and CDCs expressed similar frequencies of CD90 + and CD105 + . Both were also CD45 -with a small number expressing cKit + ( Figure  1 ). Despite these similarities, they had markedly different expression of cardiac transcription factors. Both GATA4 and Nkx2.5 were absent in MSCs but ubiquitous in CDCs with nearly all demonstrating that they were cardiac lineage committed at the time of administration.
Comparative physiological effects of icMSCs and icCDCs in swine with hibernating myocardium.
There were no differences in hemodynamic variables at rest or during adenosine between treatment groups (Supplemental Table I ). Baseline studies 3-months after instrumentation confirmed the presence of viable dysfunctional hibernating myocardium. Regional LAD wall thickening (LAD %WT) was reduced compared with normal remote regions (38±11% vs. 83±26%, p<0.01) along with reductions in resting perfusion (LAD 0.63±0.21 vs. 0.80±0.34 ml/min/g in remote, p<0.05). Adenosine-dilated flow was also attenuated (LAD 1.62±0.90 vs. 4.00±2.90 ml/min/g in remote, p<0.001). Indices of LV function and flow were comparable among all treatment groups at baseline.
The effects of icMSCs and icCDCs on regional function are summarized in Figure 2 and Supplemental Table II . One-month after treatment, LAD%WT increased in both icMSC-treated (50.7±13.4%) and icCDC-treated (50.9±16.6%) animals vs. vehicle-treated controls (33.7±9.2%; p<0.05 vs. each cell-therapy). Functional effects of cell therapy were not limited to the ischemic LAD area, as both cell types prevented the deterioration of remote zone wall thickening that was observed in vehicle-treated animals. As a result, remote zone %WT was significantly higher in animals treated with icMSCs (88.4±26.0%,) and icCDCs (94.3±39.3%) compared with vehicle-treated controls (59.5±18.2%; p<0.05 vs. each cell-therapy) 1-month after treatment. Global LV ejection fraction was minimally reduced at baseline and was not significantly affected by any treatment (Supplemental Table II ). Importantly, there were no significant differences in functional improvement comparing icMSCs vs. icCDCs. Consistent with our previous results 16 , there were no significant effects of either cell-therapy on serial measurements of coronary flow at rest or during adenosine vasodilation (Figure 3) . Although icMSCand icCDC-treated animals exhibited a significant increase in capillary density in both LAD and remote regions of the left ventricle (Figure 4) , neither treatment promoted arteriogenesis since there was no change in arteriolar density. Thus, the functional improvement afforded by icMSCs and icCDCs was accompanied by capillary angiogenesis without arteriogenesis or increased collateral blood flow.
Comparative effects of icMSCs and icCDCs on cardiomyocyte number and size.
Blinded analysis of myocyte nuclear density and diameter are summarized in Figure 5 . Nuclear density in vehicle-treated animals was reduced throughout the left ventricle (LAD: 973±181 nuclei/mm 
DISCUSSION
There are several important findings from the present study. First, using a blinded, randomized vehicle-controlled study design, we have shown that global infusion of allogeneic icMSCs and icCDCs produces comparable increases in myocardial function and myocyte proliferation. Improvements in function were associated with myocyte proliferation in both ischemic and remote myocardium. Second, while there was no functional arteriogenesis, cell therapy globally increased capillary density and myocyte nuclear density with a reduction in myocyte diameter. This, along with the observation that the number of nuclei per myocyte is unchanged, is consistent with significant myocyte proliferation throughout the left ventricle that is quantitatively similar between the two cell-therapies. Finally, the increase in myocyte nuclear number despite minimal engraftment of allogeneic cells in sex mismatched donor-recipients indicates that new myocytes are formed via endogenous mechanisms rather than direct differentiation of injected cells and is supported by the elevated expression of myocyte proliferative markers. Collectively, our results demonstrate that global intracoronary infusion of allogeneic MSCs and CDCs promotes a similar degree of myocardial repair via the stimulation of endogenous myocyte proliferation. This is the first study to directly compare allogeneic intracoronary infusion of CDCs and MSCs in a large animal model of chronic myocardial ischemia. A few studies have compared these cell types after direct intramyocardial injection into infarcted tissue. For example, following xenogeneic transplantation of human cells to immunocompromised mice with myocardial infarction, CDCs were shown to be therapeutically superior to bone marrow-derived MSCs, adipose tissue-derived MSCs, and bone marrowderived mononuclear cells 27 . Xenogeneic cell transfer of human cKit+ cardiac stem cells (CSCs) also promoted greater myocardial repair than human bone marrow-derived MSCs after injection in mice with permanent coronary artery ligation 28 . In a subsequent study using a porcine reperfused myocardial infarct model, myocardial injection of human CSCs and bone marrow-derived MSCs produced equivalent functional improvement 29 . Interestingly, the combination of human MSCs and CSCs produced greater functional improvement than either cell type alone. While not examined in our study, it is plausible that combining MSCs and CDCs could yield greater functional repair than either cell alone and should be considered in future studies.
While intracoronary infusion of both allogeneic MSCs and CDCs were efficacious, our preclinical results suggest that it may be difficult to demonstrate that either cell type would be superior to the other in a head-to-head clinical trial. The similarity of functional repair afforded by each cell type is perhaps not surprising given several similarities between MSCs and CDCs revealed by in vitro analyses. For example, using a microarray-based approach, Dey and colleagues Taken in the context of previous findings, our results add support to the emerging notion that both allogeneic MSCs and CDCs are safe and promote functional improvement. Previous studies have shown that MSCs and CDCs stimulate endogenous myocyte proliferation 15, 31, 32 and subsequent myocardial regeneration despite limited long-term engraftment of injected cells. In the present study, histological analyses indicated that only ~1 of every 10,000 new myocytes was derived from donor-derived MSCs or CDCs, yet cell-treated animals exhibited elevated markers of myocyte proliferation. Taken together, these data are consistent with the idea that exogenous MSCs and CDCs stimulate endogenous myocyte proliferation, resulting in a significant increase in myocyte number. The cellular mechanism by which endogenous myocyte proliferation is stimulated remains unclear and could not be evaluated in our large animal model. Recent data in rats indicate that a potential candidate for the reparative actions of CDCs is the secretion of microRNA-rich exosomes that, in vitro, enhance angiogenesis, promote myocyte proliferation, and decrease apoptosis 33 . There is also evidence supporting an important role of cell-to-cell contact-dependent CDC stimulation of myocyte proliferation that is mediated by β1 integrin signaling 34 .
The requirement of cell-to-cell contact to promote myocardial repair extends to MSCs as well. Hatzistergos et al. 15 demonstrated that intramyocardial injection of MSC-conditioned media (containing secreted growth factors) was not sufficient to replicate the beneficial effects of MSC injection in a porcine infarct model. Based on the limited in vivo data at hand, MSCs and CDCs are likely to facilitate endogenous myocyte repair either via cell-to-cell communication or the prolonged release of paracrine factors or exosomes from cells that are retained in the heart.
Our results also demonstrate that icMSCs and icCDCs can promote functional improvement in the absence of changes in myocardial perfusion in the setting of a chronic coronary stenosis. Indeed, the significant improvement in LAD regional wall thickening in icMSC-and icCDC-treated animals was not accompanied by changes in resting or adenosine-vasodilated perfusion. These findings are consistent with previous results in this model 16, 17 and provide further evidence that interventions that stimulate myocyte proliferation can dissociate the myocardial flow-function relationship by improving function independently of perfusion 35 . The failure of either cell type to produce measurable improvements in myocardial blood flow may relate to their inability to significantly increase arteriolar density. At the same time, both cell types stimulated capillary angiogenesis, which has been used by some as an indirect index of improved tissue perfusion. Increases in capillary number did not lead to measurable changes in resting or vasodilated perfusion in the LAD region supplied by the chronic stenosis since capillaries have a negligible contribution to total coronary vascular resistance. Interestingly, however, increases in capillary density matched increases in myocyte nuclear density with the capillary-to-myocyte ratio maintained after icMSCs and icCDCs. This matching has been described by others and may facilitate tissue oxygen exchange. The concomitant regression of cellular hypertrophy would also improve oxygen transport across the sarcolemma via reversion of the so-called "ischemic core" phenomenon. This postulates that increases in myocyte crosssectional area limit oxygen delivery to the center of the myocyte 36 . Thus, the decrease in myocyte size as well as increases in capillary density could improve oxygen transport at the cellular level.
The majority of cardiac cell therapy studies have attempted to regenerate myocytes in areas of infarction by administering cells down an infarct-related artery using "stop-flow" intracoronary infusion or to infarct border areas via transendocardial injection. However, our laboratory has demonstrated therapeutic success with global intracoronary infusion under continuous flow. This allows cells to be administered throughout the dysfunctional left ventricle, thus promoting beneficial effects in non-ischemic remote areas of the heart. From a practical standpoint, cell infusion without transient coronary occlusion or the use of transendocardial injection devices could be performed easily in any standard catheterization laboratory, thereby facilitating rapid, widespread clinical implementation. This approach is also safe with a variety of cell types, as demonstrated in the present study, as long as cells are infused prior to extended passage, filtering is performed, and an appropriate dose and rate of infusion are selected. Finally, from a clinical perspective, the amount of cyclosporine used (~3 mg/kg/day) is well below that used in organ transplantation. Although previous studies have demonstrated safety and efficacy of allogeneic MSCs and CDCs without immunosuppression 11, 37 , it is possible that short-term, low-dose cyclosporine could delay the immune response to allogeneic cells and enhance functional improvement.
Since the swine model of hibernating myocardium used in the present study is characterized by regional dysfunction of viable myocardium in the absence of scar, our results indicate that global icCDCs and icMSCs promote functional repair independent of any potential effects on infarct size. This finding may be particularly relevant in the clinical translation of intracoronary cell therapy, since many patients exhibit large areas of viable, dysfunctional myocardium with residual perfusion due to contemporary reperfusion strategies that successfully limit infarct size and preserved LV EF 38, 39 . Despite improvements in regional wall thickening, neither cell type produced significant increases in global LV function. This likely reflects the mild impairment in ejection fraction present at baseline as well as the limitations of Mmode echocardiographic assessment. Importantly, recent data from our laboratory demonstrate that global intracoronary CDC delivery can also improve global function when myocardial scar is present and global EF is reduced 40, 41 .
The cardiac cell therapy field has grown rapidly over the past decade, but attempts to translate promising preclinical findings to patients have been met with disappointment. Unfortunately, concerns over experimental design and investigator blinding, coupled with publication bias towards positive results, may deserve blame for some of this. A recent review by Rosen and Myerburg 42 contrasted the positive results of numerous unblinded or uncontrolled studies with neutral findings in randomized, blinded, and appropriately controlled trials. These same issues extend to pre-clinical studies conducted in large animal models of heart disease that serve as the pivotal step in the translation of novel cell-based therapeutic approaches 6 . The present study circumvented these limitations by employing an approach where animals were randomized to one of three treatment arms with all data coded and each investigator, research scientist and technician blinded throughout data collection and all analyses. The codified data used a common repository that was only accessible to the investigator overseeing the statistical analysis. Improvements in myocardial function, as well as the quantitative extent of new myocyte formation, were nearly identical between cell types, indicating that MSCs and CDCs exhibit comparable therapeutic potential. Fortunately, these blinded results confirm our previous findings in unblinded studies demonstrating functional repair of hibernating myocardium following global intracoronary infusion of autologous MSCs and CDCs 16, 17 .
Methodological considerations.
We used a single infusion with a comparable number of cells for each cell type that has previously demonstrated efficacy in our previous studies but differences in therapeutic efficacy could exist at alternative doses 43 . Our study design did not determine the specific component of the heterogeneous CDC population responsible for their effects. Few studies have administered CDCs fractionated using surface markers but one has suggested CD105 + /CD90 -/cKit -cells to constitute the active fraction 44 . Thus, we may have found enhanced functional improvement if this sub-population of CDCs had been administered. Like nearly all experimental studies, the donors and recipients of MSCs and CDCs in the present study were relatively young, healthy animals. Thus, clinical translation to patients may still be complicated by the fact that the target population is of advanced age with multiple cardiovascular risk factors that could impact therapeutic efficacy. Although there were not significant differences between groups in any measured variable prior to treatment, remote zone wall thickening tended to be higher (p=0.08) in animals randomized to receive icMSCs, which may have influenced our ability to compare the effects of each cell type on this parameter. In contrast to autologous MSCs 16 , MSC-treated animals in the present study did not exhibit an increase in LV mass. This could reflect differences between autologous and allogeneic cells or the impact of blinding, randomization, and the use of concurrently-treated animals. Finally, we found different relative increases in Ki67 labeling vs. pHH3 labeling 4-weeks after cell infusion vs. vehicle-treated controls. This could reflect the time course of these markers prior to tissue harvesting as well as variations in the time over which cells are Ki67 or pHH3 positive with each treatment. Recent studies have demonstrated that physiological stimuli such as revascularization itself can also stimulate cardiac repair and alter these myocyte proliferation indices 45 . Regardless of the proliferative indices measured at a single time point (which reflect a rate of myocyte division at that point in time), the increase in nuclear density and reduction in myocyte size assessed 4-weeks after treatment reflects the cumulative myocyte increase which was the same with icMSCs and icCDCs.
Conclusions.
The present study demonstrates therapeutic equipoise of two contemporary cell therapy platforms in a large animal model of chronic ischemia. Global icMSCs and icCDCs each significantly improved regional contractile function and increased myocyte number throughout the LV without affecting myocardial perfusion. These results occurred despite evidence of limited cell engraftment 1-month after treatment, implicating cell therapy-mediated stimulation of endogenous myocyte regeneration as a primary mechanism of repair for both cell types. Our preclinical study demonstrates the feasibility of implementing a rigorous blinded experimental design that is similar to that employed in single center randomized clinical trials. While the results suggest that it may be difficult to identify therapeutic superiority of either cell type over the other in clinical studies, they support their ability to produce myocyte cellular remodeling before global LV dysfunction and heart failure develop.
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